UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway

Table 1 Correlation between UBE2S expression and clinicopathological characteristics

Clinicopathological features	UBE2S expression
Clinicopathological features	Low expression	High expression	p value
Ages (years)
<56	17	24	0.974
≥ 56	33	46	0.974
FIGO staging
I + II	9	16	0.518
III + IV	41	54	0.518
CA125 (U/ml)
<600	21	24	0.373
≥ 600	22	36	0.373
Lymph node metastasis
Positive	12	26	0.017
Negative	25	18	0.017
Omentum metastasis
Positive	32	39	0.471
Negative	14	23	0.471
Platinum Status
Resistance	5	14	0.001
Sensitive	20	11	0.001

ISSN: 1757-2215